All the news Showing 10 of 79 articles from: NAFLDGet an RSS feed of these articles Show All news infohep newsEditors' picks from other sources HIV doubles the risk of liver fibrosis by middle-age, without viral hepatitis Michael Carter / 26 January 2021 Having HIV almost doubles the risk of liver fibrosis, according to European research published in the online edition of the Journal of Infectious Diseases. Investigators in Denmark and the Netherlands ... Semaglutide alone or in combination regimens shows promise for NASH Liz Highleyman / 18 December 2020 Semaglutide, a medication approved to treat type 2 diabetes, increased the likelihood of improvement in non-alcoholic steatohepatitis (NASH) without worsening liver fibrosis, researchers reported at the AASLD virtual Liver Meeting. What's more, ... Lanifibranor improves NASH in 24-week trial Keith Alcorn / 18 December 2020 Twenty-four weeks of treatment with lanifibranor, a drug designed to treat NASH, improved liver fibrosis in 42% of people treated in a phase 2b clinical trial, Professor Sven Francque of Antwerp ... Efruxifermin improves liver fat and fibrosis in people with NASH Keith Alcorn / 15 December 2020 Efruxifermin reduced liver fat and improved liver inflammation and fibrosis in the majority of people with NASH who received it in a phase 2a trial but nausea and vomiting led 10% of ... Fatty liver greatly increases vulnerability to COVID-19 in obese people Keith Alcorn / 16 November 2020 Fatty liver disease combined with obesity places people at much higher risk of severe COVID-19, analysis of British people who tested positive for SARS-CoV-2 shows. Obesity alone did not increase the risk ... Cotadutide improves metabolic and liver biomarkers in people with NAFLD and diabetes Liz Highleyman / 26 October 2020 Cotadutide, an experimental therapy that alters glucose and lipid metabolism, led to weight loss and improvements in metabolic, cardiovascular and liver fibrosis biomarkers in overweight people with diabetes and fatty liver disease, but ... Experimental NASH treatments: Gilead candidates miss primary endpoint but show some benefits Liz Highleyman / 20 October 2020 Combinations of experimental drugs for non-alcoholic steatohepatitis (NASH) failed to meet a study's primary endpoint by significantly improving liver fibrosis without worsening NASH, but one combination in particular – firsocostat plus ... Fatty liver disease common in people living with HIV and hepatitis B Keith Alcorn / 30 September 2020 Around one in three people with HIV and hepatitis B had fatty liver disease and one in ten had liver damage, US researchers from the Hepatitis B Research Network report in Clinical ... Diabetes raises the risk of liver damage in people with HIV Keith Alcorn / 21 September 2020 Almost half of people with HIV with unexplained liver enzyme elevations or other abnormal liver markers had non-alcoholic steatohepatitis (NASH) and 39 of 116 had stage F3 or F4 fibrosis, and advanced ... Aldafermin reduces liver fat in phase 2 study Keith Alcorn / 14 September 2020 Aldafermin significantly reduced liver fat content and liver damage in a phase 2 study of a 24-week treatment course, Dr Stephen Harrison, Visiting Professor of Hepatology at the University of Oxford, told ... ← First12345...8Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD NASH Experimental treatments for NASH/NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Noticeboard Email bulletins News feeds